Rate of relapses ( 55/71 [ 77.5 % ] placebo ; 16/64 [ 25 % ] pali ER ) and secondary endpoints ( change from baseline in Positive And Negative Syndrome Scale [ PANSS ] and Clinical Global Impression - Severity Scores ) were significantly lower ( p < 0.001 ) in pali ER group vs placebo , in favor of pali ER .